Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Biotech Inc. -- Ignore unavailable to you. Want to Upgrade?

To: blue_chip who wrote (23)	10/28/2000 2:51:55 PM
From: Gulo	Read Replies (1) \| Respond to of 103

Thanks Chip! The Stockhouse interview confirms that ONC is past the first stage of the trial, where they would inject a single individual for three weeks before starting the next participant. This means they have completed at least the first three individuals without concerns about significant toxicity. I like Thompsons' line about interim reports: "interim report in Phase I is not normal procedure, unless results are much better, or much worse, than expected. " I guess the absence of an interim report means the drug didn't kill anyone, and that it didn't simply wipe out any trace of cancer in the patients. Some tumor regression is expected, but because that is not the focus of the trial, it may not be reported. I think the recent market for ONC answers that question. <g> -g